Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Detection of iron deficiency anaemia in cirrhosis: Diagnostic utility of ferritin and MCV in a large UK primary care cohort

Suzanne Maynard, Cynthia Wright Drakesmith, Margaret Smith et al. Nov 03, 2025 pp. 6465-6465 10.1182/blood-2025-6465

Abstract Background: Iron deficiency anaemia (IDA) is common yet often under-evaluated in cirrhosis, where chronic inflammation complicates...

Comprehensive DNA/RNA-based targeted sequencing for molecular karyotyping and clonality assessment in newly diagnosed multiple myeloma patients

Juan Manuel Rosa-Rosa, Natalia Buenache, Iria Vazquez et al. Nov 03, 2025 pp. 2562-2562 10.1182/blood-2025-2562

Abstract Multiple myeloma (MM) is a genetically heterogeneous malignancy marked by complex clonal dynamics and a range of cytogenetic altera...

Effectiveness of second-line therapies following upfront daratumumab plus bortezomib, cyclophosphamide and dexamethasone: A new benchmark

Eugene Brailovski, Xia Wu, Grace Gallagher et al. Nov 03, 2025 pp. 5746-5746 10.1182/blood-2025-5746

Abstract Background Daratumumab plus bortezomib, cyclophosphamide and dexamethasone (D-VCd) is the only FDA-approved treatment regimen for n...

Quantitative morphological parameters of bone marrow plasma cells are predictive of outcomes in plasma cell dyscrasias

Guangqi Wang, Hualong Zhao, Enmin Song et al. Nov 03, 2025 pp. 5789-5789 10.1182/blood-2025-5789

Abstract Introduction: Morphologic evaluation of bone marrow cells remains a cornerstone of the MICM (morphology-immunophenotyping-cytogenet...

First-line romiplostim combined with immunosuppressive therapy for severe aplastic anemia: A prospective, single-arm, Phase II study

Lele Zhang, Xiang Ren, Xiangrong Hu et al. Nov 03, 2025 pp. 1426-1426 10.1182/blood-2025-1426

Abstract Background Incorporating thrombopoietin receptor agonists (TPO-RAs) into standard immunosuppressive therapy (IST) has significantly...

Cellular senescence associated with aging and chemotherapy exposure primes bone marrow for immune dysfunction and myeloma persistence

Wen-hung Chou, Julia Wang, Xiang Li et al. Nov 03, 2025 pp. 4955-4955 10.1182/blood-2025-4955

Abstract Age-related decline in immune function increases susceptibility to hematologic malignancies. Although bone marrow (BM) orchestrates...

Applying computational modelling to a high-risk multiple myeloma data set to create novel risk stratification groupings

Orthi Shahzad, Richard Norris, Niels Weinhold et al. Nov 03, 2025 pp. 5790-5790 10.1182/blood-2025-5790

Abstract Introduction: Multiple Myeloma (MM) is a heterogeneous disease making it difficult to accurately predict the di...

Ofirnoflast suppresses heme-induced inflammation, representing a novel therapeutic strategy for hemolytic anemias

Benjamin Bearss, Jared Bearss, Devan Bursey et al. Nov 03, 2025 pp. 1151-1151 10.1182/blood-2025-1151

Abstract Background: Hemolytic anemias, such as sickle cell disease, are characterized by accelerated red blood cell destruction, which resu...

Efficacy and safety of bmetl regimen (Orelabrutinib plus Semustine, Temozolomide and Lenalidomide) with subsequent maintenance treatment in elderly/frail patients with CNSL

Yawen Wang, Hongwei Xue, Wei Song et al. Nov 03, 2025 pp. 7228-7228 10.1182/blood-2025-7228

Abstract Introduction: Central nervous system lymphoma (CNSL) is an aggressive lymphoma (Radke J et al. Nat Commun. 2022), including primary...

Epigenetic basis of MDS/MPN overlap syndrome with compound loss of Kmt2c and Dnmt3a

Prabhjot Kaur, Jixiu Shan, Kalyanee Shirlekar et al. Nov 03, 2025 pp. 3247-3247 10.1182/blood-2025-3247

Abstract Monosomy 7, or loss of 7q (-7/del(7q)), is one the most common chromosomal anomalies in myelodysplastic syndromes (MDS, ~10% of pat...

First interim analysis of venetoclax real-world observational study on newly-diagnosed AML patients in Italy (VERO): Focus on patient and diseases characteristics and quality of life at baseline

Ivana Lotesoriere, Caterina Alati, lorenzo celona et al. Nov 03, 2025 pp. 5159-5159 10.1182/blood-2025-5159

Abstract Introduction The Venetoclax Real-World Observational study on effectiveness and treatment management in patients with Newly-Diagnos...

Early discharge patients have non-inferior outcomes following inpatient CAR-T infusion

Nour Nassour, Megan Herr, Nisha Nair et al. Nov 03, 2025 pp. 7680-7680 10.1182/blood-2025-7680

Abstract Administration of chimeric antigen receptor (CAR)–modified T-cell therapy has evolved to become a mainstay treatment in patient wit...

Prospective monitoring of 591 cancer patients with clonal hematopoiesis detected in daily practice

Mégane Tanguay, David Fandrei, Michael Degaud et al. Nov 03, 2025 pp. 6708-6708 10.1182/blood-2025-6708

Abstract Introduction Clonal hematopoiesis (CH) is enriched in patients with cancer and has been linked to adverse outcomes. Although often...

Pediatric cancer risk factors: A review of literature

Rebecca Emeny, Angela Ricci, Linda Titus et al. Nov 03, 2025 pp. 6839-6839 10.1182/blood-2025-6839

Abstract Introduction According to Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute (NCI), the in...

CAR T cell therapy referral patterns and characteristics of patients with relapsed or refractory (R/R) large B cell lymphoma (LBCL) in the United States

Mazyar Shadman, Fei Fei Liu, Christine Fu et al. Nov 03, 2025 pp. 6272-6272 10.1182/blood-2025-6272

Abstract Introduction: CAR T cell therapies are a pivotal advancement in the treatment of R/R LBCL that offer the potential for long-lasting...

Recombinant von willebrand factor for perioperative management of bleeding in pediatric patients with severe von willebrand disease: Interim results from a phase 3 multicenter study and a phase 3b continuation study

Shayla Bergmann, Bulent Zulfikar, Jessica Meznarich et al. Nov 03, 2025 pp. 1304-1304 10.1182/blood-2025-1304

Abstract Introduction: Von Willebrand disease (VWD) is the most common bleeding disorder in children. Recombinant von Willebrand factor (rVW...

Integrated genomic and immunophenotypic profiling of histiocytic disorders reveals therapeutic implications of differential BCL2 expression

Hind Salama, Yasir M. Alsubhi, Mohammed Omer et al. Nov 03, 2025 pp. 2986-2986 10.1182/blood-2025-2986

Abstract Background Histiocytic disorders, including Langerhans Cell Histiocytosis (LCH), Erdheim-Chester Disease (ECD), and Rosai-Dorfman D...

A randomized study of conventional chemotherapy +/- uproleselan in older adults with Acute Myeloid Leukemia eceiving intensive induction chemotherapy (Alliance A041701)

Geoffrey Uy, Jun Yin, Shira Dinner et al. Nov 03, 2025 pp. 3415-3415 10.1182/blood-2025-3415

Abstract Background. Uproleselan (GMI-1271) is an antagonist of E-selectin, an adhesion molecule expressed on endothelial cells in the vascul...

Treatment intensity and region of diagnosis affect survival in primary CNS lymphoma in England: A national cohort study from the uncover project.

Mark Bishton, Nurunnahar Akter, Indrani Karpha et al. Nov 03, 2025 pp. 6325-6325 10.1182/blood-2025-6325

Abstract Introduction. The IELSG32 study established MATRix as a standard remission induction regimen for patients ≤70 y...

Pilot study: Assessing allostatic load score and outcomes in Acute Myeloid Leukemia patients in North Carolina

Vorapat Vorapanya, Katie Moffitt, Joshua Zeidner et al. Nov 03, 2025 pp. 6916-6916 10.1182/blood-2025-6916

Abstract Background: Allostatic load (AL) represents the cumulative systemic stress burden on an individual's body, involving neuroendocrine...

Chidamide in combination with azacitidine, mitoxantrone liposomes, and prednisone (CAMP regimen) for treatment-naïve TFH-derived peripheral T-cell lymphoma

Huimin Liu, Wei Liu, Wenyang Huang et al. Nov 03, 2025 pp. 1864-1864 10.1182/blood-2025-1864

Abstract Objective: Peripheral T-cell lymphoma (PTCL) is a rare but challenging malignancy, in which the TFH (T follicular helper)-derived P...

The synonymous IDH1 p.Gly105Gly (rs11554137) variant associates with AML post-transplant relapse via aberrant signal transduction pathways

Olisaemeka Ogbue, Emma St. Martin, Oudai Alkabbani et al. Nov 03, 2025 pp. 1699-1699 10.1182/blood-2025-1699

Abstract Background Missense mutations in IDH1 are well-established therapeutic targets in acute myeloid leukemia (AML). In contrast, the sy...

Preliminary efficacy and safety of golidocitinib in relapsed/refractory T cell and NK cell large granular lymphocyte leukemia

Ying Yu, Yuxi Li, Rui Cui et al. Nov 03, 2025 pp. 3648-3648 10.1182/blood-2025-3648

Abstract Backgroud: Large granular lymphocyte leukemia (LGLL) is a rare and incurable hematologic malignancy with minimal therapeutic advance...

Efficacy and safety of FLAG and CLAG regimens (Replacing Cyclophosphamide) in conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory malignant hematologic diseases

Yanzhi Song, Zhanxiang Liu, Erhui Yuan et al. Nov 03, 2025 pp. 5993-5993 10.1182/blood-2025-5993

Abstract Background: The F (fludarabine) LAG (cytarabine+granulocyte colony-stimulating factor, G-CSF) and C (cladribine) LAG regimens have...

Scalable production and anti-tumor efficacy of iPSC-derived immortalized anti-CD19 CAR macrophages

Akihiro Nakajima, Keisuke Kirito, Sou Nakamura et al. Nov 03, 2025 pp. 5908-5908 10.1182/blood-2025-5908

Abstract Chimeric antigen receptor (CAR) -T cell therapy has shown remarkable efficacy in patients with relapsed or refractory mature B cell...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page